Teva Pharmaceutical Industries Retained Earnings (Accumulated Deficit) 2010-2024 | TEVA
Teva Pharmaceutical Industries retained earnings (accumulated deficit) from 2010 to 2024. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.
- Teva Pharmaceutical Industries retained earnings (accumulated deficit) for the quarter ending September 30, 2024 were $-14.956B, a 7.83% increase year-over-year.
- Teva Pharmaceutical Industries retained earnings (accumulated deficit) for 2023 were $-13.534B, a 4.31% increase from 2022.
- Teva Pharmaceutical Industries retained earnings (accumulated deficit) for 2022 were $-12.975B, a 23.23% increase from 2021.
- Teva Pharmaceutical Industries retained earnings (accumulated deficit) for 2021 were $-10.529B, a 3.81% decline from 2020.
Teva Pharmaceutical Industries Annual Retained Earnings (Accumulated Deficit)
(Millions of US $) |
| 2023 |
$-13,534 |
| 2022 |
$-12,975 |
| 2021 |
$-10,529 |
| 2020 |
$-10,946 |
| 2019 |
$-6,956 |
| 2018 |
$-5,958 |
| 2017 |
$-3,803 |
| 2016 |
$13,607 |
| 2015 |
$14,851 |
| 2014 |
$14,436 |
| 2013 |
$12,535 |
| 2012 |
$12,346 |
| 2011 |
$11,284 |
| 2010 |
$9,325 |
| 2009 |
$6,662 |
Teva Pharmaceutical Industries Quarterly Retained Earnings (Accumulated Deficit)
(Millions of US $) |
| 2024-09-30 |
$-14,956 |
| 2024-06-30 |
$-14,519 |
| 2024-03-31 |
$-13,673 |
| 2023-12-31 |
$-13,534 |
| 2023-09-30 |
$-13,870 |
| 2023-06-30 |
$-13,950 |
| 2023-03-31 |
$-13,086 |
| 2022-12-31 |
$-12,975 |
| 2022-09-30 |
$-11,660 |
| 2022-06-30 |
$-11,716 |
| 2022-03-31 |
$-11,484 |
| 2021-12-31 |
$-10,529 |
| 2021-09-30 |
$-10,370 |
| 2021-06-30 |
$-10,662 |
| 2021-03-31 |
$-10,869 |
| 2020-12-31 |
$-10,946 |
| 2020-09-30 |
$-11,096 |
| 2020-06-30 |
$-6,747 |
| 2020-03-31 |
$-6,887 |
| 2019-12-31 |
$-6,956 |
| 2019-09-30 |
$-7,066 |
| 2019-06-30 |
$-6,752 |
| 2019-03-31 |
$-6,063 |
| 2018-12-31 |
$-5,958 |
| 2018-09-30 |
$-3,072 |
| 2018-06-30 |
$-2,864 |
| 2018-03-31 |
$-2,688 |
| 2017-12-31 |
$-3,803 |
| 2017-09-30 |
$7,873 |
| 2017-06-30 |
$7,430 |
| 2017-03-31 |
$13,809 |
| 2016-12-31 |
$13,607 |
| 2016-09-30 |
$14,991 |
| 2016-06-30 |
$14,990 |
| 2016-03-31 |
$15,110 |
| 2015-12-31 |
$14,851 |
| 2015-09-30 |
$14,657 |
| 2015-06-30 |
$14,839 |
| 2015-03-31 |
$14,589 |
| 2014-12-31 |
$14,436 |
| 2014-09-30 |
$14,017 |
| 2014-06-30 |
$13,436 |
| 2014-03-31 |
$12,986 |
| 2013-12-31 |
$12,535 |
| 2013-09-30 |
$12,432 |
| 2013-06-30 |
$11,987 |
| 2013-03-31 |
$12,708 |
| 2012-12-31 |
$12,346 |
| 2012-09-30 |
$12,250 |
| 2012-06-30 |
$12,542 |
| 2012-03-31 |
$11,910 |
| 2011-12-31 |
$11,284 |
| 2011-09-30 |
$10,968 |
| 2011-06-30 |
$10,256 |
| 2011-03-31 |
$9,882 |
| 2010-12-31 |
$9,325 |
| 2010-09-30 |
$8,726 |
| 2010-06-30 |
$7,843 |
| 2010-03-31 |
$7,210 |
| 2009-12-31 |
$6,662 |
| 2009-09-30 |
$6,423 |
| 2009-06-30 |
$5,902 |
| 2009-03-31 |
$5,515 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$19.350B |
$15.846B |
|
Teva Pharmaceutical Industries Limited is a global pharmaceutical company that develops, manufactures, and markets both branded and generic drugs, as well as active pharmaceutical ingredients in North America, Europe, Latin America, India, and Israel. Teva's generic product portfolio includes tablets, capsules, liquids, ointments, creams, liquids, injectables, and inhalants. The company's branded products include Copaxone, Austedo, respiratory products like ProAir and Qvar and Ajovy. Teva operates through three segments, North America, Europe and International Markets, each of which includes generics, specialty and over-the-counter products. Teva acquired Allergan's generics business Actavis Generics. The company also acquired Allergan's Anda Inc. Teva acquired Auspex Pharmaceuticals and Barr. Teva has strengthened its position in Europe through its acquisition of Germany's second largest generics producer, ratiopharm.
|
